The primary goal of the M. D. Anderson Cancer Center Lymphoma SPORE Clinical Research Core is to bridge the translational research with clinical research by 1) coordinating the development of clinical trials, 2) assisting in patient accrual, 3) reporting adverse events to appropriate agencies, and 4) providing quality control on clinical trial data. The Clinical Research Core provides a critical link between clinical research and the specific projects and cores. The Clinical Research Core is co-directed by Anas Younes, MD, and Peter McLaughlin, MD. Other key members of the Clinical Research Core are the Research Nurse Manager, Coordinator of Regulatory Compliance, Data Analyst/Auditor, and Advanced Nurse Practitioner/Research Nurse. The Research Nurse Manager will be responsible for supervising all research nurses in the core and ensuring their proper training. The Coordinator of Regulatory Compliance will be responsible for all regulatory aspects of protocol submission, approval, amendments, and communication with the Institutional Review Board (IRB) and the sponsor. The data analyst/auditor will perform periodic audits on protocols, and the Advanced Practice Nurse will be responsible for continuing education for the research staff. The Clinical Research Core will provide support to all projects and investigators involved in Projects. The Clinical Research Core will interact with the Biostatistics Core for the statistical design of clinical trials and will provide clinically-based patient data to the Biostatistics Core. It will also interact with the Biospecimens Core by procuring and transporting human specimens and by providing clinical data related to the specimens. The Core will also interact with the Administrative core to coordinate studies and communication with the NCI and other lymphoma SPORE programs.

Public Health Relevance

The Clinical Research Core will coordinate all aspects of clinical research proposed in this SPORE application, including clinical trials conducted at MDACC and the UNMC. This application has 4 IRB- approved studies enrolling patients in the first year of this proposal.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA136411-03
Application #
8323552
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2013-08-31
Budget Start
2011-09-01
Budget End
2013-08-31
Support Year
3
Fiscal Year
2011
Total Cost
$45,386
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Zhang, Jun; Medeiros, L Jeffrey; Young, Ken H (2018) Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Front Oncol 8:351
Yao, Z; Deng, L; Xu-Monette, Z Y et al. (2018) Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia 32:353-363
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Dufva, Olli; Kankainen, Matti; Kelkka, Tiina et al. (2018) Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun 9:1567
Xu-Monette, Zijun Y; Zhou, Jianfeng; Young, Ken H (2018) PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131:68-83
Bouska, A; Zhang, W; Gong, Q et al. (2017) Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. Leukemia 31:83-91
Sun, Ruifang; Wang, Jinfen; Young, Ken H (2017) Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies. Crit Rev Oncog 22:527-557
Bouska, Alyssa; Bi, Chengfeng; Lone, Waseem et al. (2017) Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. Blood 130:1819-1831
Ok, Chi Young; Young, Ken H (2017) Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev 54:99-109
Yu, Li; Tu, Meifeng; Cortes, Jorge et al. (2017) Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood 129:1658-1668

Showing the most recent 10 out of 137 publications